ZONHONBIO is dedicated to the research and development of innovative drugs and improved drugs with independent intellectual property rights in the fields of central nervous system drugs, cardiovascular and pulmonary drugs, novel targeted anticancer drugs, and anti-allergic and desensitization drugs. We are also focused on the expansion of new drug indications.

View More

With years of independent innovation, our company currently possesses core technologies such as ZHPEG^®、ZHBKKS^™、ZHBody^®、ZHBiAb^®、ZHAIT^™、ZHSLIT^™、ZHPBM^™and ZHCDX^™. We have applied for more than 200 domestic and international patents, among which over 100 patents have been granted.

View More

With efficient and sustainable capabilities in independent research and innovation, ZONHONBIO has developed and established a diversified, track-specific, and differentiating leading product pipeline in the fields of central nervous system drugs, cardiovascular and pulmonary drugs, novel targeted anticancer drugs, and anti-allergic and desensitization drugs.

View More

We are establishing the Clinical Medical Research and Timely Tracking Platform, aiming to adopt a high-quality, high-efficiency, and low-cost innovative development model. ZONHONBIO takes autonomous control of key clinical development stages to ensure high-quality clinical development, meanwhile, reduces operational costs by collaborative partnerships with Contract Research Organizations (CROs).

View More